Phase I trials in paediatric oncology - The European perspective - On behalf of the New Agents Group of the United Kingdom Childrens Cancer Study Group

Investigational New Drugs

Volumn 14, Issue 1, 1996, Pages 23-32

  Estlin, E J ^a   Ablett, S ^b   Newell, D R ^c   Lewis, I J ^d   Lashford, L ^e   Pearson, A D J ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Methodology; Paediatric oncology; Phase I trial

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN; GRANISETRON; IDARUBICIN; PACLITAXEL; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN;

BLOOD TOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOXICITY; EUROPE; HUMAN; INTERNATIONAL COOPERATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL ETHICS; METHODOLOGY; MYALGIA; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STOMATITIS; TREATMENT PLANNING; VOMITING;

ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS, PHASE I; EUROPE; HUMANS; NEOPLASMS;

EID: 0029836207     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00173679     Document Type: Article

References (31)

1. Marsoni S, Ungerleider R, Hurson S, Hammershaimb L: Tolerance to antineoplastic agents in children and adults. Cancer Treatment Reports 69:1263-1269, 1985
2. nd edition. Philadelphia: JB Lippincott Company, 1993, pp 197-245
3. Smith M, Adamson P, Balis F, et al.: Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients. J Clin Oncol 10:1666-1673, 1992
4. Lee J, Newman R, Lippman S, et al.: Phase I evaluation of all-trans retinoic acid in adults with solid tumours. J Clin Oncol 11:959-966, 1993
5. Boddy AV, Calvete JA, Olson KB, Rafi I: Non-linear pharmacokinetics and metabolism of AG337, a rationally designed thymidylate synthase (TS) inhibitor. Br J Cancer 71(suppl 24):66, 1995
6. Newell DR, Pearson A, Balmanno K, et al.: Carboplatin pharmacokinetics in children: the development of a pae-diatric dosing formula. J Clin Oncol 11:2314-2323, 1993
7. Slevin M, Clark P, Joel S, et al.: A randomised trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
8. Houghton P, Cheshire P, Hallman J, Bissery M, Mathieu-Boue A, Houghton J: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-carbonyloxy-camptothecin against human tumour xenografts: lack of cross-resistance in vivo in tumours with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53:2823-2829, 1993
9. Arbuck S, Canetta R, Onetto N, Christian M: Current dosage and schedule issues in the development of paclitaxel (TAXOL). Semin Oncol 20(suppl 3):31-39, 1993
10. Calvete JA, Balmanno K, Rafi I, Newell DR, Taylor GA, Boddy AV, Lind NB, Bailey NB, Calvert AH, Webber S, Johnston A, Clendennin NJ: Pre-clinical and clinical studies of the novel thymidylate synthase inhibitor AG337, given by oral administration. Br J Cancer 71 (suppl 24): 70, 1995
11. Prendeville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M: A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. British Journal of Cancer 68:418-424, 1993
12. 111 diethylnorspermine, a polyamine analogue, in advanced cancer. Proc Am Assoc Clin Oncol 14:472, 1995
13. Pratt CB: The conduct of Phase I-II Clinical Trials in children with cancer. Med Ped Oncol 19:304-309, 1991
14. Nitschke R, Sexuer CL, Wunder S: Therapeutic choices made by patients with end-stage cancer. J Pediatrics 101:471-476, 1982
15. Furman WL, Pratt CB, Rivera GK: Mortality in pediatric Phase I clinical trials. J Natl Cancer Inst 81:1193-1194, 1989
16. CPMP Working Party on the efficacy of Medicinal Products. European Community Commission notes for guidance: Good Clinical Practice for trials of Medicinal Products in the European Community. J Pharmacol Toxicology 67:361-372, 1990
17. Lansky SB, List MA, Lansky LL, et al.: The measurement of performance in childhood cancer. Cancer 60:1651-1656, 1987
18. Korn EL, Midthune D, Chen TT, et al.: A comparison of two Phase I trial designs. Statistics in Medicine 13: 1799-1806, 1994
19. Smith MD, Ungerleider R, Reaman G, Seibel N, Bleyer WA, Vietti T, Pratt C, Trueworry R, Pearson ADJ: Considerations on the conduct of Phase I trials in children with refractory cancer. Unpublished draft document from the National Cancer Institute
20. Ettinger LJ, Gaynon PS, Kralo MD, et al.: A Phase I study of carboplatin in children with acute leukaemia in bone marrow relapse. A report from the Childrens Cancer Group. Cancer 72:917-922, 1993
21. WHO handbook for reporting results of cancer treatment. WHO offset publication 1979. 48-World Health Organisation, Geneva
22. Cheson B, Cassieth P, Head D, et al.: Report of the National Cancer Institute - Sponsored Workshop on definitions of diagnosis and response in Acute Myeloid Leukaemia. J Clin Oncol 8:813-819, 1990
23. Brodeur GM, et al.: International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988
24. Ertmann R, Bode U, Erb N, Forcadell de Bios, Gutjahr P, Haas R, Kuhn N, Siewart H, Landbeck G: Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxy-duanorubicin) in recurrent acute leukaemias in childhood. Klinishie Padiatrie 200:200-204, 1988
25. Lashford LS, Lewis U, Fielding SL, Flower MA, Meller S, Kernshead JT, Ackery D: Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Childrens Cancer Study Group investigation. J Clin Oncol 10:1889-1896, 1992
26. Negrier S, Micon J, Floret D, Boufett E, Gentet J-C, Philip I, Stamm D, Costil J, Gaspard M, Andreu G, Palmer P, Franks CR, Zucker J-M, Bernard J-L, Fridman WH, Favrot M, Philip T: Interleukin-2 and lymphocyte-activated killer cells in 15 children with advanced meta-static neuroblastoma. J Clin Oncol 9:1363-1369, 1991
27. Lemerle J, Lartigau E, Godzinski J, McDowel H, Upward J, Murdoch RD: Efficacy and safety of Granisetron in the prevention of chemotherapy induced emesis in children. Med Fed Oncol 19:420, 1991
28. Pearson ADJ, Price L, Hofer C, Lashford L, et al.: Phase I study of continuous intravenous infusion of Low Dose Thiotepa in children. Medical and Paediatric Oncology 23:270, 1994
29. Rafi I, Taylor GA, Balmanno K, Calvete JA, Boddy AV, Bailey NB, Lind MJ, Newell DR, Calvert AH, Johnston A, Clendennin N: Phase I study of the novel antifolate AG337 given by a 5 day continuous infusion. Br J Cancer 51 (suppl 24): 10, 1995
30. Marina N, Rodman J, Shema S, et al.: Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed tumours. J Clin Oncol 11:554-560, 1993
31. Evans WE, Rodman JH, Relling MV, Crom WR, Rivera GK, Pratt CB, Crist WM: Concept of maximum tolerated systemic exposure and its application to Phase I-II studies of anticancer drugs. Med Paed Oncol 19:153-159, 1991